Immunotherapy-Chemo cocktail shows promise for shrinking cervical tumors before surgery
NCT ID NCT07617818
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing whether adding an immunotherapy drug (QL1706) to standard chemotherapy before surgery can help shrink tumors in women with early-stage cervical cancer (stages IB1-IB3). About 50 participants will receive the combination, then undergo conservative surgery. The main goal is to see how many patients have no cancer left in the removed tissue. Researchers will also track side effects, survival, and tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QL1706 (a combination of two immunotherapy drugs, iparomlimab and tuvonralimab) plus cisplatin and paclitaxel chemotherapy
What this could lead to
If successful, this approach could help shrink cervical tumors before surgery, potentially allowing more women to have less extensive surgery and better long-term outcomes.
What could go wrong
This is a small, early-phase trial with only 50 participants and no comparison group. The combination may cause significant side effects, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••